TOKAI Corp. (9729) · RiskDropped
Impact of Slower Growth in the Prescription–Dispensing Separation Rate on Store Expansion
First written in FY2017. 1 of 3 entries say "Restated". Latest entry: FY2021.
3entries
5years
0from disclosures
How it moved
Same theme, other companies
Changes in Healthcare Demand and Business Conditions Driven by the Separation of Prescribing and Dispensing, Deregulation, and Population Decline and AgingA theme 4 companies write about · 4 as a headwind · 0 as a tailwind
0 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2021DroppedAnnual report
「有価証券報告書に記載した事業の状況、経理の状況等に関する事項のうち、投資者の判断に重要な影響を及ぼす可能性があると考えられる主要なリスクには、「社会保障制度の改定等によるリスク」、「従業員確保に関するリスク」があり、以下にリスクの概要等について記載しております。」
医薬分業率の伸び低下による店舗展開への影響は、本 filing では明示されていない。 - FY2018RestatedAnnual report
「If growth in the rate of pharmaceutical separation slows, this could affect the expansion of stores, including new openings, and could affect the performance of the Pharmacy Services business.」
医薬分業率の伸び低下による店舗展開・調剤業績への影響を継続している。 - FY2017First statedAnnual report
「If growth in the rate of pharmaceutical separation slows, this could affect the expansion of stores, including new openings, and could affect the performance of the Pharmacy Services business.」
Indicates that slower growth in the rate of pharmaceutical separation could affect new openings, store expansion and pharmacy business performance.